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ABSTRACT
CHD1L (chromodomain helicase/ATPase DNA binding protein 1-like gene) has 
been demonstrated as an oncogene in hepatocellular carcinoma (HCC), however, 
the role of CHD1L in non-small-cell lung cancer (NSCLC) tumorigenesis hasn’t 
been elucidated. In this study, the expression and amplification status of CHD1L 
were examined by immunohistochemistry and fluorescence in situ hybridization 
respectively in 248 surgically resected NSCLCs. The associations between CHD1L 
expression and clinicopathologic features and the prognostic value of CHD1L were 
analyzed. Overexpression and amplification of CHD1L was found in 42.1% and 17.7% 
of NSCLCs, respectively. The frequency of CHD1L overexpression (53.2% vs. 28.1%, 
P = 0.002) and amplification (25.2% vs. 8.2%, P = 0.020) in adenocarcinoma (ADC), 
was much higher than that in squamous cell carcinoma (SCC). CHD1L overexpression 
was associated closely with ascending pN status (P < 0.001), advanced clinical stage 
(P = 0.001) and tumor distant metastasis (P = 0.001) in ADCs, but not in SCCs. For the 
whole cohort and ADC patients, univariate survival analysis demonstrated a significant 
association of CHD1L overexpression with shortened survival; and in multivariate 
analysis, CHD1L overexpression was evaluated as a independent predictor for 
overall survival and distant metastasis free survival. These results suggested that 
overexpression of CHD1L is positively associated with tumor metastasis of lung ADC, 
and might serve as a novel prognostic biomarker and potential therapeutic target for 
lung ADC patients.
INTRODUCTION
Lung cancer is the leading cause of cancer deaths 
worldwide [1]. Non-small-cell lung cancer (NSCLC), 
which accounts for almost 80% of such death, is a 
very heterogeneous group of malignancies [2]. Even 
for earlier stages patients, a significant proportion of 
them will suffer from local recurrence and/or distant 
metastasis after radical surgery [3]. However, the 
international staging system is still inadequate to 
reliably predict patients’ prognosis. Since chromosomal 
aberrations are believed to play an important role 
in tumor progression [4], it will be of great value to 
search the specific gene alterations in NSCLC which 
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can provide additional staging information to optimize 
individual therapy.
Chromodomain helicase/ATPase DNA binding 
protein 1-like gene (CHD1L) is a newly identified 
oncogene that we previously isolated from a frequently 
amplified region at chromosome 1q of human 
hepatocellular carcinoma (HCC) [5]. A series of our 
further studies demonstrated that CHD1L contributes 
to HCC cell migration, invasion and metastasis, and is 
positively associated with tumor progression in HCC 
patients [5–7]. Recently, CHD1L has also been reported 
as a novel biomarker for patients’ prognosis in several 
types of solid tumor, including breast cancer [8], gastric 
cancer [9], colorectal cancer [10], bladder cancer [11] and 
ovarian cancer [12]. To date, however, the abnormalities 
of CHD1L and its oncogenic role in NSCLC have not 
been studied. Since amplification of 1q, in which the 
CHD1L gene is located, was frequently examined in 
NSCLC and correlated closely with tumor recurrence and 
metastasis [13, 14], we conducted this study to examine 
the expression and amplification dynamics of CHD1L in a 
large cohort of NSCLC patients, and its clinicopathologic 
and prognostic significance was further evaluated.
RESULTS
Expression of CHD1L in NSCLCs
The expression of CHD1L could be informatively 
examined by IHC in 233/248 (93.9%) of the NSCLCs 
and 27/30 (90.0%) of normal lung tissues. The non-
informative samples included unrepresentative samples, 
samples with too few tumor cells (<300 cells per case) and 
lost samples, which we didn’t use in our data compilation. 
Since the expression scores of CHD1L in normal lung 
tissues varied from 0 to 2 (intensity 0–2, proportion 0–1), 
overexpression of CHD1L was designated when the score 
was equal or more than 3. Using this criteria, CHD1L 
overexpression was observed in 98/233 (42.1%) of the 
NSCLCs, 58/109 (53.2%) of the adenocarcinomas (ADCs) 
and 25/89 (28.1%) of the squamous cell carcinomas 
(SCCs), respectively (Fig. 1).
Association between CHD1L expression and 
clinic-pathological variables in NSCLCs
The associations between CHD1L expression and 
several clinico-pathological variables in NSCLC patients 
are assessed and displayed in Table 1. Overexpression 
of CHDIL in NSCLCs was significantly associated 
with tumor histology (P = 0.002), advanced pN status 
(P < 0.001) and advanced stage (P < 0.001). There was 
no significant association between CHD1L expression 
and other clinic-pathological features, such as patients’ 
age, gender, tumor grade, pT status, surgical procedure, 
adjuvant chemotherapy and adjuvant radiotherapy. We 
further evaluated the associations in ADC and SCC 
patients, respectively, and found that the significant 
associations between CHD1L overexpression and 
advanced pN status/ advanced stage were only seen in 
ADC patients, but not in SCC cases (Table 1).
Association between CHD1L expression and 
post-surgical failure patterns
During the median observation period of 
46.1 months (range 3.6–199.3 months) for all patients, 
67 experienced local-regional failure, 109 experienced 
distant metastasis, and 173 had cancer-specific death. The 
failure patterns of the NSCLC patients are presented in 
Table 2. The incidence of distant metastasis was much 
higher in patients with CHD1L overexpression than those 
with CHD1L normal expression for all patients (56.9% 
vs. 43.1%, P < 0.001); however, in subgroup analysis, 
this significant association was only seen in ADC patients 
(P < 0.001) and not in SCC patients (P = 0.162). No 
significant incidence difference was found in local-
regional recurrence between groups with CHD1L normal/
overexpression for all patients, SCC patients or ADC 
patients (P > 0.05, Table 2).
The impact of CHD1L expression on NSCLC 
patients’ survival
In univariate analysis, CHD1L overexpression was 
evaluated to correlate closely with shorten overall survival 
(OS), shorten local-regional failure free survival (LRFFS) 
and shorten distant metastasis free survival (DMFS) for 
the whole cohort and the ADC patients, but not for the 
SCC patients (Fig. 2). Besides CHDIL overexpression, the 
impact value of age, gender, tumor grade, histology, stage, 
surgical procedure, adjuvant chemotherapy and adjuvant 
radiotherapy have also been tested in univariate analysis 
for OS, LRFFS and DMFS, respectively. Variables that 
showed a significant impact on patients’ survival for the 
whole cohort and the ADC patients in univariate analysis 
were listed in Table 3, which were further tested in 
multivariate analysis. Other variables, including tumor 
grade, surgical procedure, adjuvant chemotherapy and 
adjuvant radiotherapy, were not evaluated as significant 
prognostic factors in univariate analysis (Data not shown). 
Our multivariate analysis results showed that CHD1L 
overexpression was evaluated as an independent predictor 
of poor OS and poor DMFS for the whole cohort and ADC 
patients (Table 3).
Amplification of CHD1L in NSCLCs
The FISH analysis was informative in 50.0% 
(15/30) of the normal lung tissues and 52.4% (130/248) 
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of the NCSLCs. The main reasons for most of the 
non-informative cases were samples without FISH signal 
and samples with weak target signals or those with a 
strong signal background. Amplification of CHD1L was 
not detected in any of the normal lung tissues, but was 
observed in 17.7% (23/130) of the informative NSCLCs. 
In univariate analysis by Cox regression models, CHD1L 
amplification was evaluated as a significant predictor 
for distant metastasis (hazard ratios (HR) = 3.255, 95% 
confidence intervals (CI) = 1.984–5.339, P < 0.001), 
recurrence (HR = 2.795, 95% CI = 1.426–5.481, 
P = 0.003) and OS (HR = 3.185, 95% CI = 2.039–4.975, 
P < 0.001).
In our study, 117 cases were shown to be 
simultaneously informative by both IHC and FISH tests. 
Amplification of CHD1L gene was significantly associated 
with CHD1L protein overexpression (P < 0.001) and 
tumor histology (P = 0.020, Table 4). The frequency of 
CHD1L amplification in ADC (25.5%) was much higher 
than that in SCC (8.2%). Overexpression of CHD1L was 
observed in the majority (16/19, 84.2%) of NSCLCs with 
CHD1L amplification; whereas, CHD1L overexpression 
can also be detected in 35.7% (35/98) of the NSCLCs 
without CHD1L gene amplification.
DISCUSSION
In this study, our results showed that the expression 
of CHDIL in all of the normal lung tissue specimens 
was absent or at low levels; in contrast, overexpression 
of CHDIL was frequently examined in many of the 
NSCLC specimens. Moreover, the frequency of CHDIL 
overexpression increased with an ascending pN status 
and advancing clinical stage in NSCLC, especially in 
Figure 1: Immunohistochemical stainings of CHDIL and FISH assay of CHDIL gene in NSCLC tissues. A. A normal lung 
tissue (case 19) showed a negative staining of CHDIL in all the epithelium cells (×100). B. A squamous carcinoma of lung (case 115) showed 
normal expression of CHDIL with a negative staining of CHDIL in all tumor cells (×100). C. Overexpression of CHDIL was detected in a 
squamous carcinoma of lung (case 216), in which about 50% of tumor cells were observed moderate positive staining of CHDIL (×100). 
D. Overexpression of CHDIL was detected in an adenocarcinoma of lung (case 57), in which about 40% of tumor cells were observed 
strong positive staining of CHDIL (×100). E. Overexpression of CHDIL was examined in an adenocarcinoma of lung (case 113), in which 
about 60% of tumor cells showed strong positive staining of CHDIL (×100). F. Amplification of CHDIL gene was examined by FISH in the 
same case of lung adenocarcinoma (case 113), in which CHDIL gene signals (red) were detected at least 3 times more than chromosome 1 
centromere signals (green) (×1000).
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Table 1: CHD1L expression and clinic-pathological variables
Total CHD1L protein
Characteristics cases Informative Overexpression (%) P*
Age (years) 0.780
 ≤59† 130 119 49 (41.2)
 >59 118 114 49 (43.0)
Gender 0.190
 Male 181 172 68 (39.5)
 Female 67 61 30 (49.2)
Tumor grade 0.521
 G1 24 22 8 (36.4)
 G2 173 164 67 (40.9)
 G3 51 47 23 (48.9)
Histology 0.002
 SCC 94 89 25 (28.1)
 ADC 113 109 58 (53.2)
 Others‡ 41 35 15 (42.9)
pT status 0.139
 pT1–2 147 139 53 (38.1)
 pT3–4 101 94 45 (47.9)
pN status <0.001
 pN0 120 113 31 (27.4)
 pN1 49 46 20 (43.5)
 pN2 79 74 47 (63.5)
Stage <0.001
 I 82 80 22 (27.5)
 II 59 57 20 (35.1)
 III 107 96 56 58.3)
Surgical procedure 0.405
 Lobectomy 223 209 86 (41.1)
 Pneumonectomy 25 24 12 (50.0)
Adjuvant 
chemotherapy 0.126
 Yes 89 82 40 (48.8)
 No 159 151 58 (38.4)
Adjuvant radiotherapy 0.670
 Yes 35 33 15 (45.5)
 No 213 200 83 (41.5)
(Continued)
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lung ADCs. Similar results were also observed in other 
types of human cancer [6, 8, 9]. In HCC, overexpression 
of CHD1L was associated closely with microsatellite 
formation and venous invasion [6]. In gastric cancer, 
up-regulated expression of CHD1L was reported to be 
correlated with tumor depth, nodal involvement and 
distant metastasis [9]. While in breast cancer, presence 
of CHD1L expression was associated with higher Ki-67 
index and HER2 amplification [8]. These findings suggest 
that increased expression of CHD1L is associated with 
aggressive tumor biology in certain types of human solid 
tumors, including lung ADC.
Interestingly, we found that the expression level 
of CHDIL in NSCLCs was significantly associated with 
tumor histology. On the basis of cell morphology, ADC 
and SCC are the two most common types of NSCLC. 
Given the difference in biological and clinical behavior 
of the two types of NSCLC, the patterns of chromosomal 
aberrations in ADC and SCC are thought to be different 
to some extent [15]. One of the differences between the 
2 types of NSCLC is that 1q amplification was more 
common in ADC as compared to that in SCC [14, 16, 
17]. Since CHD1L is an oncogene locates at a frequently 
amplified region of 1q [5], our results which showed that 
the frequency of CHDIL overexpression and the frequency 
of CHDIL amplification in ADC were much higher than 
those in SCC, is in agreement with the previous reports.
Most importantly, overexpression of CHD1L was 
significantly associated the present of post-operation 
distant metastasis, and was evaluated as an independent 
adverse predictor of OS and DMFS for lung ADC patients. 
As we know, lung ADC is a highly malignant disease 
which tends to disseminate haematogeneously at an early 
stage. Even after a curative resection, the majority patients 
still die within 5 years because of tumor metastasis [1], 
thus, effective adjuvant treatment are actually needed. 
However, the benefit of adjuvant chemotherapy is still 
limited [18, 19], and the available target therapy agents 
Total CHD1L protein
Characteristics cases Informative Overexpression (%) P*
SCC subgroup
 pN status 0.753
  pN0 49 48 12 (25.0)
  pN1 18 17 5 (29.4)
  pN2 27 24 8 (33.3)
 Stage 0.568
  I 33 32 8 (25.0)
  II 25 22 5 (22.7)
  III 36 35 12 (34.3)
ADC subgroup
 pN status <0.001
  pN0 53 49 15 (30.6)
  pN1 22 22 12 (54.5)
  pN2 38 38 31 (81.6)
 Stage 0.001
  I 38 37 12 (32.4)
  II 27 25 12 (48.0)
  III 48 47 34 (72.3)
*Chi-square test;
†Mean age;
‡Others include adenosquamous cell carcinoma, anaplastic large-cell carcinoma, sarcoma, adenoid cystic carcinoma, 
mucoepidermoid carcinoma and carcinoid tumor.
Abbreviation: CHD1L, chromodomain helicase/ATPase DNA binding protein 1-like gene; G, grade; SCC, squamous cell 
carcinoma; ADC, adenocarcinoma; pT, pathological tumor; pN, pathological node.
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are quite rare. Thus, identification of more potential 
therapeutic targets is still highly desirable. When 
compared the chromosomal imbalances between primary 
and metastatic lung ADC, Goeze et al [14] reported that 
DNA overrepresentation on 1q was the most common 
alteration. And the overrepresentations on 1q21–q25 were 
evaluated to be associated with the metastatic phenotype 
of lung ADC [14]. Our results, together with these 
findings, suggest that up-regulated expression of CHD1L, 
a gene locates at 1q21, may provide a selective advantage 
in metastasis process of lung ADC; and CHD1L might 
be served as a potential therapeutic target for lung ADC 
patients.
With regard to the mechanism of up-regulated 
protein expression of CHD1L in NSCLCs, it is well 
established that overexpression of an oncogene is often 
caused by DNA amplification. Amplification of CHDIL 
has been detected in 50.6% of HCCs [5] and 18.3% of 
colorectal cancer samples [10]. However, none of the 
previous studies has evaluated the association of CHDIL 
gene amplification and CHDIL protein overexpression 
in any types of human cancers. To determine whether or 
not overexpression of CHD1L in NSCLCs was caused by 
gene amplification, we further examined the amplification 
status of CHD1L by FISH and tested its association with 
CHD1L expression. We observed that overexpression of 
CHDIL protein was associated, but not always coincided 
with CHDIL gene amplification in NSCLC. This result 
indicates that gene amplification might be one of the 
mechanisms that produce an excess of CHDIL protein; 
however, the modification of CHDIL expression could 
also be regulated by other mechanisms, such as post-
translational modification.
When come to the gene function of CHD1L, it has 
not been well clarified in human cancers except for HCC. 
Our previous studies showed that increased expression of 
CHD1L promoted tumor cell migration and metastasis 
by increasing cell motility and inducing epithelial-
mesenchymal transition (EMT) in HCC [6]. And this 
procedure was completed via ARHGEF9-mediated Cdc42 
Table 2: Comparison of the failure patterns between NSCLC patients with CHD1L overexpression 
and normal expression
CHD1L protein
No.
Normal 
expression (%)
Overexpression 
(%) P*
All patients
  Local-regional 
recurrence No 166 102 (61.4) 64 (38.6) 0.088
Yes 67 33 (49.3) 34 (50.7)
 Distant metastasis No 124 88 (71.0) 36 (29.0) <0.001
Yes 109 47 (43.1) 62 (56.9)
SCC
  Local-regional 
recurrence No 58 45 (77.6) 13 (22.4) 0.103
Yes 31 19 (61.3) 12 (38.7)
 Distant metastasis No 63 48 (76.2) 15( 23.8) 0.162
Yes 26 16 (61.5) 10 (38.5)
ADC
  Local-regional 
recurrence No 81 40 (49.4) 41 (50.6) 0.356
Yes 28 11 (39.3) 17 (60.7)
 Distant metastasis No 48 31 (64.6) 17 (35.4) 0.001
Yes 61 20 (32.8) 41 (67.2)
*Chi-square test.
Abbreviation: CHD1L, chromodomain helicase/ATPase DNA binding protein 1-like gene; NSCLC, non-small-cell lung 
carcinoma; SCC, squamous cell carcinoma; ADC, adenocarcinoma.
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Figure 2: Survival curves according to CHDIL expression level for NSCLC patients. A, B. and C. overall survival for the 
whole cohort, SCC and ADC patients; D, E. and F. local-regional failure free survival for the whole cohort, SCC and ADC patients; and 
G, H. and I. distant metastasis free survival for the whole cohort, SCC and ADC patients. CHDIL normal expression groups are shown as 
solid lines; CHDIL overexpression groups are shown as dashed lines.
Table 3: Multivariate Cox regression analysis for OS, LRFFS and DRFS
OS LRFFS DMFS
Variables HR (95%CI) P HR (95%CI) P HR (95%CI) P
ALL patients
 Age† 1.406 (1.042–1.897) 0.026 – –
1.379 (0.945–
2.011) 0.095
 Histology‡ 1.269 (0.924–1.744) 0.142 – –
2.154 (1.375–
3.372) 0.001
 Stage§ 1.745 (1.436–2.121) <0.001
3.365(2.284–
4.958) <0.001
1.764 (1.374–
2.264) <0.001
  CHD1L 
expression¶
1.526 (1.120–
2.079) 0.007
1.432(0.881–
2.328 ) 0.148
1.755(1.185–
2.599) 0.005
ADE patients – – – – – –
 Age† 1.295 (0.836–2.005) 0.247 – – – –
 Stage§ 1.994 (1.477–2.691) <0.001
5.800(2.779–
12.107) <0.001
2.102 (1.480–
2.984) <0.001
  CHD1L 
expression¶
1.720 (1.091–
2.712) 0.020
1.478(0.681–
3.208) 0.323
2.019 (1.168–
3.491) 0.012
†Age > 59 yrs vs. Age ≤ 59 yrs;
‡Non squamous cell carcinoma vs Squamous cell carcinoma;
§Stage III vs. Stage II vs. Stage I;
¶Overexpression vs. Normal expression.
Abbreviation: CHD1L, chromodomain helicase/ATPase DNA binding protein 1-like gene; OS, overall survival; LRFFS, 
local-regional failure free survival; DMFS, distant metastasis free survival.
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activation [6]. More recently, we have also found that 
CHD1L promoted HCC cell invasiveness and metastasis 
by activating kazal-like domains proteoglycan 1 
(SPOCK1) -AKt signaling pathway [20]. Collectively, 
both CHD1L-ARHGEF9-Cdc42-EMT pathway and 
CHD1L-SPOCK1-AKt pathway might be involved in 
HCC progression and metastasis. However, the specific 
underling mechanisms of CHD1L in lung ADC metastasis 
have not been investigated. Clearly, further functional 
studies are needed.
Our study did have some limitations. It is a 
retrospective study, we didn’t include all the clinical 
information because of the unavailability of some data. 
And there was a high heterogeneity in the regimens and 
cycles of adjuvant chemotherapy that we could not further 
analyzed. Thus, further studies are needed to confirm these 
results.
In summary, our results provide some evidences 
for the concept that (1) overexpression of CHD1L might 
provide a selective advantage for distant metastasis 
of lung ADC; and (2) CHD1L plays an adverse role in 
the prognosis of lung ADC, and might serve as a novel 
prognostic marker and potential therapeutic target for lung 
ADC patients.
PATIENTS AND METHODS
Patients and tissue specimens
In this study, paraffin-embedded tissue samples 
from 248 NSCLC patients were obtained from the 
Pathology Department of Cancer Center, Sun Yat-sen 
University, Guangzhou, China, between February 1994 
and January 1998. All the selected patients had received 
complete resection (223 had lobectomy and 25 underwent 
pneumonectomy) and with adequate follow-up data. 
Patients who had preoperative treatment or those who had 
a second malignant disease were excluded.
Data regarding stage was according to the pathology 
Tumor-Node-Metastasis (pTNM) system (AJCC/
UICC 2007). Tumor differentiation and histotype were 
according to the World Health Organization classification 
for NSCLC. Local/regional failure was defined as the 
recurrence of the primary tumor and regional lymph 
nodes, while distant failure was defined as the metastasis 
to any site beyond the primary tumor and regional lymph 
nodes. The study was approved by the medical ethics 
committee of Cancer Center, Sun Yat-Sen University 
and was performed in accordance with the Declaration of 
Helsinki.
Construction of tissue microarrays (TMA)
The TMA was constructed according to a method 
described previously [21]. Briefly, the formalin-fixed, 
paraffin-embedded tissue blocks and the corresponding 
histological H&E stained slides were overlaid for tissue 
TMA sampling. The tissues (248 NSCLC and 30 normal 
lung tissues taken from regions that were not affected of 
the same patients) were sampled using a tissue arraying 
instrument (Beecher Instruments, Silver Spring, MD); 
a 0.6-mm-diameter cylinder of tissue was removed. 
Subsequently, we re-embedded the tissue cylinder into a 
predetermined position in a recipient paraffin block. Three 
cores of sample were selected from each primary NSCLC 
and normal lung tissue, and multiple sections (5 μm thick) 
were cut from the TMA block and mounted on microscope 
slides.
Immunohistochemistry (IHC)
The IHC study of CHD1L was performed using a 
standard streptavidinperoxidase method as previously 
described [12]. The TMA sections were deparaffinized 
and rehydrated. The endogenous peroxidase activity 
was blocked with 3% H2O2 for 10 minutes. For the 
antigen retrieval, slides were immersed in 10 mM 
citrate buffer (pH 6.0) and boiled in a microwave oven 
for 15 minutes. Non-specific binding was blocked by 
5% normal goat serum for 10 minutes. The slides were 
Table 4: Association of CHD1L expression and amplification in NSCLC
Informative  
cases
CHD1L gene
P*No amplification Amplification
CHD1L protein <0.001
 Normal expression 66 63 (95.5) 3 (4.5)
 Overexpression 51 35 (68.6) 16 (31.4)
Histology 0.020
 SCC 49 45 (91.8) 4 (8.2)
 ADC 55 41 (74.5) 14 (25.5)
*Chi-square test.
Abbreviation: CHD1L, chromodomain helicase/ATPase DNA binding protein 1-like gene; NSCLC, non-small-cell lung 
carcinoma; SCC, squamous cell carcinoma; ADC, adenocarcinoma.
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incubated with a 1:100 dilution of monoclonal antibody 
against CHD1L (Abcam) at 4°C overnight in a moist 
chamber. The slides were sequentially incubated with 
biotinylated goat anti-mouse IgG (1:100 dilution; Santa 
Cruz Biotechnology) and then streptavidin-peroxidase 
conjugate, each for 30 minutes at room temperature. 
Isotope-matched human IgG was used in each case as a 
negative control. Finally, the 3, 5-diaminobenzidine (DAB) 
Substrate Kit (Dako) was used for color development 
followed by Mayer hematoxylin counterstaining.
Positive expression of CHD1L in normal and 
malignant lung tissues was primarily a nuclear pattern 
(Fig. 1). For the evaluation of CHD1L staining, a semi-
quantitative scoring criterion was used, in which both 
staining intensity and positive cells percentage were 
recorded [9, 12]. A staining index (with values from 0 to 
12) was obtained as the intensity of CHDIL staining 
(0 = negative, 1 = weakly positive, 2 = moderate 
positive, 3 = strongly positive) times the proportion of 
immunopositive tumor cells (0% = 0, <10% = 1, 10% to 
<50% = 2, 50% to <75% = 3, ≥75% = 4). A minimum 
of 300 epithelial cells was counted for each case. Two 
independent pathologists (Dr. Xie D and Chen JW) 
blinded to the clinicopathologic information performed the 
scorings. The inter-observer disagreements (about 6% of 
the total informative cases) were reviewed a second time, 
followed by a conclusive judgment by both pathologists.
Fluorescence in situ hybridization (FISH)
Two-color FISH was applied to the sections of 
TMA. The BAC clone (RP11–337C18) at 1q21 containing 
the CHD1L gene probe and the chromosome 1 centromere 
probe were labeled with Spectrum-red and Spectrum-
green (Vysis, Downers Grove, IL), respectively. The 
FISH reaction was performed as described previously 
with slight modification. Briefly, the deparaffinized TMA 
section was treated with proteinase K (400 μg/ml) at 37°C 
for 45 min, followed by denaturing in 70% formamide, 
2 × SSC at 75°C for 6 min. Fifty nanograms of each probe 
were mixed in a 20μl hybridization mixture (containing 
55% formamide, 2 × SSC, and 2 μg human Cot1 DNA), 
denatured at 75°C for 5 minutes and then hybridized to 
the denatured TMA section at 37°C for 24 hours. After 
washing, the TMA section was counterstained with 
1 μg/ ml DAPI in an anti-fade solution and examined with 
a Zeiss Axiophot microscope equipped with a triple-band 
pass filter. A minimum of 300 tumor cells was evaluated 
per specimen. Amplification of CHD1L gene were 
defined as the presence (in ≥20% of tumor cells) of either 
6 (or more) gene signals or more than 3 times as many 
gene signals than reference chromosome 1 centromere 
signals (Fig. 1F) [22–24]. All samples not meeting the 
criteria for gain or amplification were considered normal. 
Control hybridizations to normal fibroblasts and to 
normal epithelial cells were performed to confirm that 
the hybridization efficiency of the test and reference 
probes was similar. The slides were assessed by the 
two independent pathologists (Dr. Xie D and Chen JW) 
mentioned above. The inter-observer disagreements 
(about 3% of the total informative cases) were reviewed a 
second time, followed by a conclusive judgment by both 
pathologists.
Statistical analysis
Statistical analysis was performed with the SPSS 
software (SPSS Standard version 13.0, SPSS Inc. Chicago, 
IL). The association of CHD1L protein expression with 
NSCLC patient’s clinicopathological features and 
its correlation with CHD1L gene amplification were 
assessed by the Chi-square test. DMFS, LRFFS and OS 
were defined as the time from the date of diagnosis to 
tumor metastasis, local-regional tumor recurrence and 
death, respectively. Survival curves were assessed by 
the Kaplan-Meier method and compared by the log-rank 
test. Cox regression analysis was carried out to assess the 
significance of variables for survival. Two-sided, P < 0.05 
was considered statistically significant.
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